Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03665077 · ClinicalTrials.gov registry record · NA
Evaluation of Blood/Imaging Based Biomarkers, Aromatase Inhibitor Induced Musculoskeletal Syndrome
A NA study of Breast Cancer and Aromatase Inhibitor Induced Musculoskeletal Syndrome (AIMSS), sponsored by University of Arizona.
- Completed
- Registry status
- NA
- Development phase
- 28
- Enrollment target
- 1
- Study location
NCT03665077 is a NA study of Breast Cancer and Aromatase Inhibitor Induced Musculoskeletal Syndrome (AIMSS) that has completed, run by University of Arizona. The registered enrollment target is 28 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03665077, a NA study of Breast Cancer and Aromatase Inhibitor Induced Musculoskeletal Syndrome (AIMSS), has completed, sponsored by University of Arizona.
- COMPLETED
- Registry status
- NA
- Development phase
- 28 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a pilot trial to evaluate for blood and imaging biomarkers in patients with breast cancer scheduled to start adjuvant hormonal therapy.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Initial blood draw
- DIAGNOSTIC_TEST Initial SWE ultrasound
- DIAGNOSTIC_TEST Blood draw at three months
- DIAGNOSTIC_TEST Blood draw at six months
- DIAGNOSTIC_TEST SWE ultrasound at six months
Study Locations (1)
Arizona
- University of Arizona Cancer Center - Tucson
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2018-02-28 |
| Est. Completion | 2022-06-15 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03665077
The ClinicalTrials.gov registry entry for NCT03665077 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (99% lower). The listed sponsor is University of Arizona, which has 349 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Breast Cancer appearing as the primary indexed condition, and to 5 interventions - of which Initial blood draw is the first listed.
NCT03665077 reports 1 study location spanning 1 distinct geographic area - top geographies include Arizona.
Frequently Asked Questions
What is clinical trial NCT03665077 about?
NCT03665077 is a clinical study titled "Evaluation of Blood/Imaging Based Biomarkers, Aromatase Inhibitor Induced Musculoskeletal Syndrome". This is a pilot trial to evaluate for blood and imaging biomarkers in patients with breast cancer scheduled to start adjuvant hormonal therapy.
What is the current status of trial NCT03665077?
This trial is currently completed. It is a NA study. The enrollment target is 28 participants. The study started on 2018-02-28. Estimated completion is 2022-06-15.
What conditions does trial NCT03665077 study?
This clinical trial studies the following conditions: Breast Cancer, Aromatase Inhibitor Induced Musculoskeletal Syndrome (AIMSS).
What interventions are being tested in trial NCT03665077?
The interventions under investigation include: Initial blood draw (DIAGNOSTIC_TEST), Initial SWE ultrasound (DIAGNOSTIC_TEST), Blood draw at three months (DIAGNOSTIC_TEST), Blood draw at six months (DIAGNOSTIC_TEST), SWE ultrasound at six months (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT03665077?
This trial is sponsored by University of Arizona, which has 349 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03665077 being conducted?
This trial has 1 study location across Arizona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Harnessing Analysis RNA Expression and Molecular Subtype to Optimize Novel TherapY MBCA
RECRUITING · NA
-
Post-operative Radiotherapy Omission in Selected Patients With Early Breast Cancer Trial International VErsion (PROSPECTIVE)
RECRUITING · NA
-
Resistance and Aerobic Exercise for Prevention in Women With Dense Breasts (REP-D)
RECRUITING · NA
-
Partial Breast Re-irradiation Using Ultra Hypofractionation (PRESERVE)
RECRUITING · NA
-
A Randomized Controlled Trial (RCT) to Determine the Efficacy of a Multidisciplinary CBT Based Pain Management Program for the Treatment of Aromatase Inhibitor Associated Musculoskeletal Symptoms (AIMSS) in Breast Cancer Survivors
RECRUITING · NA
-
Precise Oncology Interventions in Nutrition and Training (OnPoint)
RECRUITING · NA
Explore more on PlainTrial
Breast Cancer
All registered trials for this condition
Aromatase Inhibitor Induced Musculoskeletal Syndrome (AIMSS)
All registered trials for this condition
Arizona
All trials with a study site in Arizona
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.